Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Biomarkers in Alzheimer's and Parkinson's Diseases for IA

NCT: NCT07651085 · ACTIVE_NOT_RECRUITING

NCT IDNCT07651085
StatusACTIVE_NOT_RECRUITING
Start Date2024-02-08
Completion2027-07-20
SponsorIRCCS San Raffaele Roma (OTHER)
First posted
Last updated

Brief Summary

Investigate whether endogenous and exogenous risk factors, the presence of pathological amyloid aggregates and alpha-synuclein in the CSF, brain connectivity, and some clinical and biological indices such as vigilance, general motility, the sleep-wake cycle, genomic instability and possible DNA damage may correlate with (or predict) the clinical condition of mild cognitive impairment (MCI) and dementia in patients with Alzheimer's disease (AD) and Parkinson's disease (PD).

Frequently Asked Questions

What is Biomarkers in Alzheimer's and Parkinson's Diseases for IA?

Biomarkers in Alzheimer's and Parkinson's Diseases for IA is a clinical trial registered under NCT07651085. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT07651085?

The current status of NCT07651085 (Biomarkers in Alzheimer's and Parkinson's Diseases for IA) is: ACTIVE_NOT_RECRUITING.

When did Biomarkers in Alzheimer's and Parkinson's Diseases for IA start?

Biomarkers in Alzheimer's and Parkinson's Diseases for IA started on 2024-02-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.